Literature DB >> 28510612

Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil.

Tomasz Przybyła1, Monika Sakowicz-Burkiewicz1, Izabela Maciejewska1, Hanna Bielarczyk2, Tadeusz Pawełczyk1.   

Abstract

Adjuvant chemotherapy with 5-fluorouracil remains the basic treatment for patients with advanced colorectal carcinoma. The major obstacle in successful treatment is the ability of CRC cells to acquire chemoresistance. Here we examined the impact of ID1 silencing on the sensitivity of CRC cells to 5-FU. To suppress ID1 expression in HT-29 and HCT-116 cells the cells were transduced with a lentiviral vector carrying the ID1 silencing sequence. Cells with silenced ID1 showed altered expression of epithelial and mesenchymal markers and exhibited increased proliferation rate compared to the parental cells. HCT-116 cells with suppressed ID1 became sensitized to 5-FU and this was not observed in HT-29 cells. Silencing ID1 resulted in altered expression of genes encoding enzymes metabolizing 5-FU. HT-29 cells with suppressed ID1 had significantly reduced mRNA level for thymidine phosphorylase, uridine-cytydine kinase 2 and dihydropyrimidine dehydrogenase. ID1 suppression in HCT-116 cells resulted in an increase of mRNA level for thymidine phosphorylase, thymidine kinase and uridine-cytydine kinase 2 with concurrent drop of dihydropyrimidine dehydrogenase and thymidylate synthetase mRNA levels. In conclusion, ID1 expression impacts the sensitivity of colon cancer cells to 5-FU and may be considered as a potential predictive marker in CRC treatment.

Entities:  

Keywords:  5-fluorouracil; DYPD; ID1; TK; TYMP; TYMS.; UCK2; colon cancer

Mesh:

Substances:

Year:  2017        PMID: 28510612     DOI: 10.18388/abp.2016_1421

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  5 in total

Review 1.  The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression.

Authors:  Yi Fu; Xin-Dong Wei; Luoting Guo; Kai Wu; Jiamei Le; Yujie Ma; Xiaoni Kong; Ying Tong; Hailong Wu
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

2.  Inhibitor of DNA binding 1 (Id1) mediates stemness of colorectal cancer cells through the Id1-c-Myc-PLAC8 axis via the Wnt/β-catenin and Shh signaling pathways.

Authors:  Yanxia Sun; Xiaolan Lai; Yue Yu; Jieyu Li; Lei Cao; Wansong Lin; Chuanzhong Huang; Jinrong Liao; Wei Chen; Chao Li; Chunkang Yang; Mingang Ying; Qiang Chen; Yunbin Ye
Journal:  Cancer Manag Res       Date:  2019-07-23       Impact factor: 3.989

3.  SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.

Authors:  Jian Wu; Min Zhang; Omar Faruq; Eldad Zacksenhaus; Wenming Chen; Aijun Liu; Hong Chang
Journal:  Biomark Res       Date:  2021-06-16

4.  Heavy ion mutagenesis combined with triclosan screening provides a new strategy for improving the arachidonic acid yield in Mortierella alpina.

Authors:  Huidan Zhang; Dong Lu; Xin Li; Yingang Feng; Qiu Cui; Xiaojin Song
Journal:  BMC Biotechnol       Date:  2018-05-02       Impact factor: 2.563

Review 5.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.